OncoMatch/Clinical Trials/NCT05528952
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Is NCT05528952 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab · Bevacizumab · UCPVax — The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV, BCLC C, BCLC B STAGE NOT ELIGIBLE TO LOCO-REGIONAL THERAPY (Barcelona Clinic Liver Cancer (BCLC))
Locally advanced, metastatic, or unresectable disease; BCLC C stage or BCLC B stage not eligible to loco-regional therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy
Cannot have received: anti-PD-L1 therapy
Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy
Cannot have received: anti-CTLA-4 therapy
Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy
Cannot have received: immune therapy
Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy
Lab requirements
Liver function
Child-Pugh Class A status
Cardiac function
known cardiac failure of unstable coronaropathy
Child-Pugh Class A status; Inadequate organ functions: known cardiac failure of unstable coronaropathy, respiratory failure, or uncontrolled infection or another life-risk condition
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05528952 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV or BCLC C or BCLC B STAGE NOT ELIGIBLE TO LOCO-REGIONAL THERAPY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages